AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month target […]
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Moderate Buy" from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
The stock market’s optimism wave recently saw a break after latest data showed that the US labor market remains resilient despite consistent rate hikes to curb inflation.
Ergoteles LLC grew its position in AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) by 1,095.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 418,902 shares of the company’s stock after purchasing an additional 383,854 shares during the period. Ergoteles LLC’s holdings in AbCellera Biologics were worth $2,706,000 at the end of the […]